Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 6 to 7 amino acid residues in defined sequence
Reexamination Certificate
2011-01-04
2011-01-04
Kosar, Andrew D (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
6 to 7 amino acid residues in defined sequence
Reexamination Certificate
active
07863416
ABSTRACT:
The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds include agents exhibiting agonist activity and antagonist activity when exposed to the human ORL-1 receptor. As such, the hexapeptides may be useful as analgesics, anxiolytics, diuretics, and anti-cancer agents.
REFERENCES:
patent: 5821219 (1998-10-01), Grandy et al.
patent: 6011006 (2000-01-01), Thomsen et al.
patent: 7049287 (2006-05-01), Judd
patent: 7244701 (2007-07-01), Larsen et al.
patent: 7550425 (2009-06-01), Larsen et al.
patent: 2001/0011092 (2001-08-01), Tulshian et al.
patent: 1072263 (2001-01-01), None
patent: WO 99/44627 (1999-09-01), None
patent: WO 01/98324 (2001-12-01), None
Khroyan, Taline V., et al., “Anti-Nociceptive and Anti-Allodynic Effects of a High Affinity NOP Hexapepetide [Ac-RY(3-C1)YRWR-NH2] (Syn 1020) in Rodents,” ScienceDirect, Jan. 17, 2007, pp. 29-35.
Judd, A. K., et al., “Structure-Activity Studies on High Affinity NOP-Active Hexapeptides,” J. Peptide Res., 2004, 64, pp. 87-94.
Judd, A.K., et al., “N-Terminal Modifications Leading to Peptide ORL1 Partial Agonists and Antagonists,” J. Peptide Res., 2003, 62, pp. 191-198.
Encyclopedia Britannica, http://www.search.eb.com/eb/article?tocid=233942, Nov. 8, 2004.
Wikipedia, http://en.wikipedia.org/wiki/analgesic, Oct. 6, 2004.
Calo, Girolamo, et al., “Pharmacological Profile of Nociceptin/Orphanin FQ Receptors,” Clinical and Experimental Pharmacology and Physiology, 29, 2002, 223-228.
Thomsen, Christian, et al., “[3H]ac-RYYRWK-NH2, a Novel Specific Radioligand for the Nociceptin/Orphanin FQ Receptor,” Naunyn-Schmiedeberg's Arch Pharmacol (2000), 362:538-545.
Corbett et al., “Characterization of the ORL1 Receptor on Adrenergic Nerves in the Rat Anococcygeus Muscle,” British Journal of Pharmacology, pp. 349-355, 2000.
Minks, Caroline, et al., “Towards New Protein Engineering: In Vivo Building and Folding of Protein Shuttles for Drug Delivery and Targeting by the Selective Pressure Incorporation (SPI) Method,” Tetrahedron, Elsevier Science Ltd., (2000), 9431-9442.
Kawamoto, Hiroshi, et al., “Discovery of the First Potent and Selective Small Molecule Opioid Receptor-like (ORL1) Antagonist: 1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperodyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397),” Journal of Medicinal Chemistry, vol. 42, No. 25, Dec. 16, 1999, pp. 1-3.
Dooley et al., “113 Potent Orphanin FQ Receptor Ligands Identified Using Combinatorial Libraries,” The European Peptide Society, pp. 343-344, 1998.
Dooley, Colette T., et al., “Binding and In Vitro Activities of Peptides with High Affinity for the Nociceptin/Orphanin FQ Receptor, ORL1,” The Journal of Pharmacology and Experimental Therapeutics, vol. 283, No. 2, pp. 735-741, 1997.
On-line Medical Dictionary, Nov. 18, 1997, http://cancerweb.ncl.ac.uk./cgi-bin.omd?modify.
Khroyan, T.V., et al., “High Affinity Hexapeptides for ORL1 Receptors: In Vitro Activity and In Vivo Nociceptive Effects,” No. 124.
J. Rudinger, Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence, Peptide Hormones, University Park Press, Jun. 1976, pp. 1-7
Kirton & McConkie
Kosar Andrew D
Metcalf Craig
Synvax, Inc.
LandOfFree
Nociceptin-based analgesics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nociceptin-based analgesics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nociceptin-based analgesics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2727537